522 related articles for article (PubMed ID: 10678259)
1. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
[TBL] [Abstract][Full Text] [Related]
2. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
[TBL] [Abstract][Full Text] [Related]
3. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
[TBL] [Abstract][Full Text] [Related]
4. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
5. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
[TBL] [Abstract][Full Text] [Related]
6. Effect of orlistat on cardiovascular disease risk in obese adults.
Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
[TBL] [Abstract][Full Text] [Related]
7. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
Muls E; Kolanowski J; Scheen A; Van Gaal L;
Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
[TBL] [Abstract][Full Text] [Related]
8. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
de Castro JJ; Dias T; Chambel P; Carvalheiro M; Correia LG; Guerreiro L; Marques O; Medina JL; Nobre E; Nunes JS; Pereiraa MC; Polónia J; Portugal J; Raimundo A; Ruas A; da Silva PM; Vasconcelos C; Reis JL; Teles AG
Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
[TBL] [Abstract][Full Text] [Related]
9. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
Anderson JW; Schwartz SM; Hauptman J; Boldrin M; Rossi M; Bansal V; Hale CA
Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
[TBL] [Abstract][Full Text] [Related]
10. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.
Madsen EL; Bruun JM; Skogstrand K; Hougaard DM; Christiansen T; Richelsen B
Metabolism; 2009 Jul; 58(7):946-53. PubMed ID: 19409578
[TBL] [Abstract][Full Text] [Related]
11. Orlistat.
Wong NN; Cheng-Lai A
Heart Dis; 2000; 2(2):174-81. PubMed ID: 11728255
[TBL] [Abstract][Full Text] [Related]
12. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT
Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
[TBL] [Abstract][Full Text] [Related]
13. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.
Svendsen M; Helgeland M; Tonstad S
J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
Lacey LA; Wolf A; O'shea D; Erny S; Ruof J
Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.
Erdmann J; Lippl F; Klose G; Schusdziarra V
Aliment Pharmacol Ther; 2004 Jun; 19(11):1173-9. PubMed ID: 15153170
[TBL] [Abstract][Full Text] [Related]
16. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial.
Grilo CM; Masheb RM; Salant SL
Biol Psychiatry; 2005 May; 57(10):1193-201. PubMed ID: 15866560
[TBL] [Abstract][Full Text] [Related]
17. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M
Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204
[TBL] [Abstract][Full Text] [Related]
18. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Arnold ME; Steinberg CM
Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
[TBL] [Abstract][Full Text] [Related]
19. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
Kopelman P; Bryson A; Hickling R; Rissanen A; Rossner S; Toubro S; Valensi P
Int J Obes (Lond); 2007 Mar; 31(3):494-9. PubMed ID: 16953261
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
